Lippincott ® NursingCenter ® Wolters Kluwer Logo

Mavacamten (CAMZYOS) First-in-Class Small-Molecule Myosin Inhibitor for Treatment of Obstructive Hypertrophic Cardiomyopathy

Join NursingCenter to access all articles

Source:

Clinical Nurse Specialist: The Journal for Advanced Nursing Practice

May/June 2024, Volume 38 Number 3 , p 119 - 121

Earn 1.5 Contact Hours

This article has an associated Continuing Education component.
Cost for CE: $17.95.
Expires June 06, 2025. Go to CE Details Go to article

Authors

  1. O'Malley , Patricia Anne

CE Resources

Nursing Resources

About NursingCenter

 

© 2024 Wolters Kluwer Health, Inc. and/or its subsidiaries. All rights reserved. – Terms & Conditions – Privacy Policy – Disclaimer – Your California Privacy Choices -- v09.09.00